KADCYLA 20 mg/mL
ADO-TRASTUZUMAB EMTANSINE · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · Genentech, Inc.
KADCYLA is a injection, powder, lyophilized, for solution containing ado-trastuzumab emtansine at 20 mg/mL, taken intravenous. Manufactured by Genentech, Inc..
Key Facts
- Brand Name
- KADCYLA
- Generic Name
- ADO-TRASTUZUMAB EMTANSINE
- NDC Code (Product)
50242-088- Manufacturer
- Genentech, Inc.
- Strength
- 20 mg/mL
- Dosage Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA125427
- Marketing Start
- 02/22/2013
Recall History
No Recall HistoryFrequently Asked Questions
What is KADCYLA used for?
KADCYLA contains ADO-TRASTUZUMAB EMTANSINE. It is a injection, powder, lyophilized, for solution taken intravenous. Consult your doctor for specific uses.
Is KADCYLA a controlled substance?
KADCYLA is not classified as a controlled substance by the DEA.
What is the generic name for KADCYLA?
The generic name for KADCYLA is ADO-TRASTUZUMAB EMTANSINE. There are no other listed brand versions of ADO-TRASTUZUMAB EMTANSINE.
What is the NDC code for KADCYLA 20 mg/mL?
The NDC (National Drug Code) for KADCYLA 20 mg/mL is 50242-088, listed by Genentech, Inc..
Other KADCYLA Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)